Last updated: 2026-10-14 12:51:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Atea Pharmaceuticals, Inc. (AVIR) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $4.98, with a market capitalisation of $403.43M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.87 to $6.45. This page covers its latest market performance, valuation, price trends and company information.
$403.43M | |
$5.03 | |
$94.17 | |
$2.46 | |
$5.03 | |
242.99K | |
297.72K | |
-- | |
$6.45 | |
$2.87 | |
-- | |
-- |
Atea Pharmaceuticals, Inc. (AVIR) is trading at $5.03 in pre-market trading as of 2026-10-13 23:31:00, unchanged from the previous close of $5.03
Pre-market trading shows how investors are pricing AVIR before the regular session opens. The current pre-market price is near the previous close, indicating neutral early trading sentiment.
Over the past seven days, Atea Pharmaceuticals, Inc. (AVIR) moved from $5.13 to $4.98, representing a decline of 2.85% ($0.15).
The stock traded between $4.87 and $5.23 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 255.79 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 59.1%
AVIR is currently trading at $4.98, placing it 59.1% of the way from its 52-week low of $2.87 to its 52-week high of $6.45. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 55 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Atea Pharmaceuticals, Inc. (AVIR) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.